| Symbol | IOVA |
|---|---|
| Name | IOVANCE BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 825 INDUSTRIAL ROAD,SUITE 100, SAN CARLOS, California, 94070, United States |
| Telephone | +1 650 - 260-7120 |
| Fax | — |
| — | |
| Website | https://www.iovance.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001425205 |
| Description | Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patients immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Additional info from NASDAQ: |
2026-05-13 21:00
Kirby Daniel Gordon 🟡 adjusted position in 2.4K shares (1 derivative) of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) at $3.70 Transaction Date: May 11, 2026 | Filing ID: 060356
Read more
2026-05-12 12:17
New Form SCHEDULE 13G - IOVANCE BIOTHERAPEUTICS, INC. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000249 <b>Size:</b> 8 KB
Read more
2026-05-07 13:18
(30% Negative) IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Reports Q2 2026 Financial Results
Read more
2026-05-07 11:05
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Read more
2026-04-28 18:05
New Form DEFA14A - IOVANCE BIOTHERAPEUTICS, INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050467 <b>Size:</b> 431 KB
Read more
2026-04-28 18:01
New Form DEF 14A - IOVANCE BIOTHERAPEUTICS, INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050458 <b>Size:</b> 3 MB
Read more
2026-04-27 12:01
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
Read more
2026-04-17 21:15
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read more
2026-04-17 18:01
New Form PRE 14A - IOVANCE BIOTHERAPEUTICS, INC. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001104659-26-044958 <b>Size:</b> 3 MB
Read more
2026-03-27 10:52
New Form SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0000102909-26-001540 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05398640 | Expanded Access Program of AMTAGVI That is Out of Specification for Commercial … | — | Unresectable Melanoma | Available | — | — | ClinicalTrials.gov |
| NCT07192900 | Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease | Phase1 | Malignant Pleural Effusion | Recruiting | 2026-03-01 | 2037-12-01 | ClinicalTrials.gov |
| NCT07288073 | TIL Therapy in cSCC and MCC | Phase2 | Cutaneous Squamous Cell Carcinoma | Recruiting | 2026-02-10 | 2029-06-29 | ClinicalTrials.gov |
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced … | Phase2 | Melanoma (Skin Cancer) | Active_Not_Recruiting | 2025-11-28 | 2033-12-01 | ClinicalTrials.gov |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced … | Phase1 | HPV-Associated Cervical Carcinoma | Recruiting | 2025-08-11 | 2026-10-01 | ClinicalTrials.gov |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advan… | Phase1 | Unresectable Melanoma | Recruiting | 2025-03-11 | 2032-07-01 | ClinicalTrials.gov |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResec… | Phase1 | Stage IIIB Melanoma | Withdrawn | 2024-12-02 | 2028-07-01 | ClinicalTrials.gov |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced … | Phase2 | Endometrial Cancer | Recruiting | 2024-10-29 | 2029-11-01 | ClinicalTrials.gov |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, an… | Phase1 | Soft Tissue Sarcoma | Active_Not_Recruiting | 2024-03-28 | 2028-07-01 | ClinicalTrials.gov |
| NCT06151847 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and I… | Phase2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Completed | 2023-12-21 | 2025-07-10 | ClinicalTrials.gov |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembro… | Phase3 | Metastatic Melanoma | Recruiting | 2023-03-30 | 2030-03-01 | ClinicalTrials.gov |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Phase2 | Cervical Cancer | Recruiting | 2023-03-07 | 2027-01-01 | ClinicalTrials.gov |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | Phase1 | Metastatic Melanoma | Active_Not_Recruiting | 2022-11-25 | 2026-11-01 | ClinicalTrials.gov |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferent… | Phase1 | Uveal Melanoma | Recruiting | 2022-11-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Phase1 | Gastric Cancer | Recruiting | 2022-09-26 | 2028-12-31 | ClinicalTrials.gov |
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Ad… | Phase1 | Unresectable Melanoma | Recruiting | 2022-07-20 | 2027-06-01 | ClinicalTrials.gov |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Trea… | Phase1 | Locally Advanced Melanoma | Active_Not_Recruiting | 2022-07-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase2 | Metastatic Non Small Cell Lung Cancer | Recruiting | 2021-05-07 | 2031-12-01 | ClinicalTrials.gov |
| NCT04155710 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients W… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2020-02-19 | 2024-12-02 | ClinicalTrials.gov |
| NCT04111510 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastati… | Phase2 | Metastatic Triple Negative Breast Cancer | Completed | 2019-12-23 | 2023-05-11 | ClinicalTrials.gov |
| NCT04052334 | Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent an… | Phase1 | Sarcoma | Completed | 2019-09-27 | 2023-06-16 | ClinicalTrials.gov |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treati… | Phase2 | Metastatic Bladder Urothelial Carcinoma | Withdrawn | 2019-06-20 | 2023-05-01 | ClinicalTrials.gov |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase2 | Metastatic Melanoma | Terminated | 2019-05-07 | 2026-02-20 | ClinicalTrials.gov |
| NCT03671512 | Standard Root Planing vs. Periodontal Structure Repair Device for Treatment of … | Na | Periodontal Diseases | Completed | 2018-12-06 | 2020-03-09 | ClinicalTrials.gov |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Rec… | Phase2 | Malignant Solid Neoplasm | Terminated | 2018-10-16 | 2024-08-21 | ClinicalTrials.gov |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Ca… | Phase2 | Bone Sarcoma | Active_Not_Recruiting | 2018-04-27 | 2027-04-30 | ClinicalTrials.gov |
| NCT03419559 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durva… | Phase2 | Non Small Cell Lung Cancer | Withdrawn | 2018-02-28 | 2024-12-01 | ClinicalTrials.gov |
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell L… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2017-10-11 | 2023-06-09 | ClinicalTrials.gov |
| NCT03108495 | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of … | Phase2 | Cervical Carcinoma | Terminated | 2017-06-22 | 2025-08-22 | ClinicalTrials.gov |
| NCT03083873 | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Trea… | Phase2 | Squamous Cell Carcinoma of the Head and Neck | Completed | 2017-01-09 | 2022-08-08 | ClinicalTrials.gov |
| NCT02652455 | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic… | Early_Phase1 | Melanoma (Skin) | Completed | 2016-03-08 | 2020-08-30 | ClinicalTrials.gov |
| NCT02360579 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the… | Phase2 | Metastatic Melanoma | Completed | 2015-09-24 | 2024-10-24 | ClinicalTrials.gov |
| NCT01937468 | Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory … | Phase1 | Chronic Graft Versus Host Disease | Active_Not_Recruiting | 2013-11-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT01701674 | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 … | Na | Metastatic Melanoma | Completed | 2012-10-09 | 2025-08-21 | ClinicalTrials.gov |
Total clinical trials: 34
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nab paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | TERMINATED | NCT03645928 |
| Durvalumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03419559 |
| LN-145 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03419559 |
| Aldesleukin | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Fludarabine Phosphate | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Fludarabine | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Cyclophosphamide | Other | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Standard Root Planing | Other | Approved | Periodontal Diseases | COMPLETED | NCT03671512 |
| Periodontal Structure Repair (PSR) | Other | Approved | Periodontal Diseases | COMPLETED | NCT03671512 |
| Standard Root Planing | Other | Approved | Periodontal Diseases | COMPLETED | NCT03671512 |
| Periodontal Structure Repair (PSR) | Other | Approved | Periodontal Diseases | COMPLETED | NCT03671512 |
| Interleukin-2 (IL2) | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Tumor-infiltrating Lymphocyte Therapy | Drug | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Fludarabine | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Cyclophosphamide | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Nivolumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Tumor-infiltrating Lymphocytes (TIL) | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| LN-145-S1 | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT03083873 |
| LN-145 | Other | Phase PHASE2 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT03083873 |
| Tumor infiltrating lymphocytes (TIL) LN-145 | Other | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT04111510 |
| IOV-4001 | Other | Phase PHASE1 | Unresectable Melanoma | RECRUITING | NCT05361174 |
| Aldesleukin | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05483491 |
| KK-LC-1 TCR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05483491 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Interleukin-2 | Other | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Fludarabine | Other | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Cyclophosphamide | Other | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL | Other | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Pembrolizumab | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Interleukin-2 (IL-2) | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Fludarabine | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Mesna | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Cyclophosphamide | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| LN-144 | Other | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Paclitaxel | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Nivolumab-relatlimab | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Ipilimumab | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| LN-145-S1 | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| LN-145 | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Interleukin-2 | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| TIL Infusion | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Fludarabine | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Cyclophosphamide | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| CD137 | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Surgery to Remove Tumor for Growth of TIL | Procedure | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Nivolumab | Other | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Lifileucel (LN-144) | Other | Phase PHASE1 | Metastatic Melanoma | ACTIVE_NOT_RECRUITING | NCT05640193 |
| LN-145 + pembrolizumab | Other | Phase PHASE2 | Cervical Carcinoma | TERMINATED | NCT03108495 |
| LN-145 | Other | Phase PHASE2 | Cervical Carcinoma | TERMINATED | NCT03108495 |
| Questionnaire Administration | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Nivolumab | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Ipilimumab | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Fludarabine | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Cyclophosphamide | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Aldesleukin | Other | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| LN-145 | Other | Phase PHASE2 | Metastatic Non Small Cell Lung Cancer | RECRUITING | NCT04614103 |
| Lifileucel | Other | Phase PHASE2 | Endometrial Cancer | RECRUITING | NCT06481592 |
| IOV-3001 | Other | Phase PHASE1 | Unresectable Melanoma | RECRUITING | NCT06940739 |
| Adoptive Cell Therapy with TIL | Drug | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| High Dose IL-2 | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Fludarabine as Part of Lymphodepletion | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Cyclophosphamide as Part of Lymphodepletion | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Administration of Lymphodepletion | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Tumor Infiltrating Lymphocytes (TIL) | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Ipilimumab | Other | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| IL-2 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| High dose IL-2 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| Low dose IL-2 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| IOV-2001 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| Interleukin-2 | Other | Phase PHASE1 | Malignant Pleural Effusion | RECRUITING | NCT07192900 |
| locally manufactured adoptive cellular therapy (ACT) product | Drug | Phase PHASE1 | Malignant Pleural Effusion | RECRUITING | NCT07192900 |
| Lifileucel (LN-144/LN-145) | Other | Phase PHASE1 | Uveal Melanoma | RECRUITING | NCT05607095 |
| Interleukin-2 | Other | Phase PHASE1 | Chronic Graft Versus Host Disease | ACTIVE_NOT_RECRUITING | NCT01937468 |
| Treg-enriched infusion | Other | Phase PHASE1 | Chronic Graft Versus Host Disease | ACTIVE_NOT_RECRUITING | NCT01937468 |
| Interleukin-2 | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| Fludarabine | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| Cyclophosphamide | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| LN-145 | Other | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| Cyclophosphamide | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT04052334 |
| Fludarabine | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT04052334 |
| Interleukin-2 | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT04052334 |
| TIL | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT04052334 |
| Therapeutic Conventional Surgery | Procedure | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| Lifileucel | Other | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| Fludarabine | Other | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| Cyclophosphamide | Other | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| Aldesleukin | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05686226 |
| E7 TCR-T cells | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05686226 |
| Aldesleukin | Other | Phase PHASE1 | HPV-Associated Cervical Carcinoma | RECRUITING | NCT05639972 |
| E7 TCR-T cells | Other | Phase PHASE1 | HPV-Associated Cervical Carcinoma | RECRUITING | NCT05639972 |
| Lifileucel | Other | Phase PHASE2 | Metastatic Melanoma | COMPLETED | NCT02360579 |
| Pembrolizumab with Optional Crossover Period | Other | Phase PHASE3 | Metastatic Melanoma | RECRUITING | NCT05727904 |
| Lifileucel plus Pembrolizumab | Other | Phase PHASE3 | Metastatic Melanoma | RECRUITING | NCT05727904 |
| LN-145/LN-144 | Other | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06566092 |
| Lifileucel | Other | Phase PHASE2 | Melanoma (Skin Cancer) | ACTIVE_NOT_RECRUITING | NCT07288203 |
| OOS AMTAGVI | Other | Preclinical | Unresectable Melanoma | AVAILABLE | NCT05398640 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Tumor Resection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Lifileucel | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Interleukin-2 | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Fludarabine | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Echocardiography | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Cyclophosphamide | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| Biospecimen Collection | Other | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | COMPLETED | NCT06151847 |
| locally manufactured adoptive cellular therapy (ACT) product | BIOLOGICAL | Phase PHASE1 | Malignant Pleural Effusion | RECRUITING | NCT07192900 |
| IOV-3001 | BIOLOGICAL | Phase PHASE1 | Unresectable Melanoma | RECRUITING | NCT06940739 |
| LN-145/LN-144 | BIOLOGICAL | Phase PHASE1 | Soft Tissue Sarcoma | ACTIVE_NOT_RECRUITING | NCT06566092 |
| Interleukin-2 (IL-2) | BIOLOGICAL | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Mesna | DRUG | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| LN-144 | BIOLOGICAL | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Tumor Resection | PROCEDURE | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | RECRUITING | NCT06151847 |
| Multigated Acquisition Scan | PROCEDURE | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | RECRUITING | NCT06151847 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | RECRUITING | NCT06151847 |
| Echocardiography | PROCEDURE | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | RECRUITING | NCT06151847 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | RECRUITING | NCT06151847 |
| Pembrolizumab with Optional Crossover Period | BIOLOGICAL | Phase PHASE3 | Metastatic Melanoma | RECRUITING | NCT05727904 |
| Lifileucel plus Pembrolizumab | BIOLOGICAL | Phase PHASE3 | Metastatic Melanoma | RECRUITING | NCT05727904 |
| Lifileucel (LN-144) | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | ACTIVE_NOT_RECRUITING | NCT05640193 |
| E7 TCR-T cells | BIOLOGICAL | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05686226 |
| Lifileucel (LN-144/LN-145) | BIOLOGICAL | Phase PHASE1 | Uveal Melanoma | RECRUITING | NCT05607095 |
| KK-LC-1 TCR-T cells | BIOLOGICAL | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05483491 |
| OOS AMTAGVI | BIOLOGICAL | Preclinical | Unresectable Melanoma | AVAILABLE | NCT05398640 |
| IOV-4001 | BIOLOGICAL | Phase PHASE1 | Unresectable Melanoma | RECRUITING | NCT05361174 |
| Therapeutic Conventional Surgery | PROCEDURE | Phase PHASE1 | Locally Advanced Melanoma | ACTIVE_NOT_RECRUITING | NCT05176470 |
| IL-2 | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| High dose IL-2 | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| Low dose IL-2 | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| IOV-2001 | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT04155710 |
| Tumor infiltrating lymphocytes (TIL) LN-145 | DRUG | Phase PHASE2 | Metastatic Triple Negative Breast Cancer | COMPLETED | NCT04111510 |
| TIL | DRUG | Phase PHASE1 | Sarcoma | COMPLETED | NCT04052334 |
| Fludarabine Phosphate | DRUG | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Pemetrexed | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Nab-Paclitaxel | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Paclitaxel | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Carboplatin | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Cisplatin | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Nivolumab-relatlimab | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Pembrolizumab | DRUG | Phase PHASE1 | Stage IIIB Melanoma | WITHDRAWN | NCT06190249 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL | BIOLOGICAL | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Malignant Solid Neoplasm | TERMINATED | NCT03610490 |
| Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | BIOLOGICAL | Phase PHASE2 | Bone Sarcoma | ACTIVE_NOT_RECRUITING | NCT03449108 |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | BIOLOGICAL | Phase PHASE2 | Metastatic Bladder Urothelial Carcinoma | WITHDRAWN | NCT03935347 |
| Aldesleukin | DRUG | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05686226 |
| Durvalumab | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03419559 |
| Interleukin-2 (IL2) | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Tumor-infiltrating Lymphocyte Therapy | OTHER | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| Tumor-infiltrating Lymphocytes (TIL) | PROCEDURE | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT03215810 |
| LN-145 + pembrolizumab | BIOLOGICAL | Phase PHASE2 | Cervical Carcinoma | TERMINATED | NCT03108495 |
| LN-145-S1 | BIOLOGICAL | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| LN-145 | BIOLOGICAL | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| TIL Infusion | BIOLOGICAL | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Fludarabine | DRUG | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| CD137 | DRUG | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Surgery to Remove Tumor for Growth of TIL | PROCEDURE | Phase EARLY_PHASE1 | Melanoma (Skin) | COMPLETED | NCT02652455 |
| Nivolumab | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
| Lifileucel | BIOLOGICAL | Phase PHASE2 | Melanoma (Skin Cancer) | RECRUITING | NCT07288203 |
| Interleukin-2 | BIOLOGICAL | Phase PHASE2 | Cutaneous Squamous Cell Carcinoma | RECRUITING | NCT07288073 |
| Treg-enriched infusion | OTHER | Phase PHASE1 | Chronic Graft Versus Host Disease | ACTIVE_NOT_RECRUITING | NCT01937468 |
| Adoptive Cell Therapy with TIL | BIOLOGICAL | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| High Dose IL-2 | DRUG | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Fludarabine as Part of Lymphodepletion | DRUG | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Cyclophosphamide as Part of Lymphodepletion | DRUG | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Administration of Lymphodepletion | DRUG | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Tumor Infiltrating Lymphocytes (TIL) | PROCEDURE | Approved | Metastatic Melanoma | COMPLETED | NCT01701674 |
| Ipilimumab | DRUG | Phase PHASE2 | Metastatic Melanoma | RECRUITING | NCT03645928 |
Total products: 321